Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These findings do not support testing stage I or II colorectal tumors for BRAF mutations, although additional large studies are needed.
|
29660527 |
2019 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation.
|
29127628 |
2019 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Vemurafenib doesn't shrink BRAF-mutated colorectal tumors, but a regimen that also includes irinotecan and cetuximab improves vemurafenib's effectiveness, more than doubling progression-free survival in patients with metastatic tumors.
|
28153858 |
2017 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We did not detect BRAF mutations in patients with double somatic colorectal tumors or Lynch syndrome.
|
27302833 |
2016 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The studies were divided into five groups: (1) distribution of KRAS/BRAF mutations in distal and proximal colorectal cancer, the summary OR value was 1.24 versus 4.03, (2) distribution of KRAS/BRAF mutations in CIMP-low/Neg and CIMP-high (CIMP-H) tumors, the summary OR value was 0.77 versus 10.49, (3) distribution of KRAS/BRAF mutations in MSI-low (MSI-L)/microsatellite stable (MSS) and MSI-high (MSI-H) tumors, the summary OR value was 0.51 versus 9.60, (4) proportion of CIMP-H/MSI-H tumors among distal and proximal colorectal tumors, the summary OR value was 3.66 versus 6.54, and (5) proportion of CIMP-H tumors among MSI-L/MSS and MSI-H tumors, the summary OR value was 5.87.
|
28230016 |
2016 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
|
27222248 |
2016 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Microsatellite instability: an update.
|
25701956 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
|
25517872 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This article reviews the current knowledge on the use and implications of BRAF mutational status in colorectal tumors, in order to define its present role in the clinical practice.
|
25975986 |
2015 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
|
25989278 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A previous analysis revealed that around 80% of colorectal tumors carrying a mutation in BRAF also overexpress splice variant Rac1b.
|
26341689 |
2015 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
|
25239454 |
2014 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
|
24163374 |
2014 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.
|
24594804 |
2014 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression.
|
25280562 |
2014 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We recently reported that microRNA-31 (miR-31) is associated with BRAF mutation in colorectal tumors.
|
24752710 |
2014 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However, genomic, epigenomic and molecular pathology testings (for example, analyses for microsatellite instability, MLH1 promoter CpG island methylation, and KRAS and BRAF mutations in colorectal tumors) are becoming routine clinical practices.
|
23792451 |
2014 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
|
23812671 |
2013 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To verify the technical characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot codons 12 and 13 and of the BRAF(V600E) mutation in colorectal tumor, we selected 75 samples previously characterized by conventional and CO-amplification at Lower Denaturation temperature-PCR (COLD-PCR) followed by High Resolution Melting analysis and direct sequencing.
|
23536897 |
2013 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The LR in favor of pathogenicity was estimated to be ~12-fold for a colorectal tumor with a BRAF mutation-negative MSI-H phenotype.
|
22949379 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
|
23845441 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
23325582 |
2013 |